A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Trial ID:
IRB-22-7924
Darren Sigal, M.D.
This study will test the safety and effectiveness of an investigational drug, OBI-3424, given once every three weeks by intravenous (IV) infusion in patients with advanced solid tumor cancer. This is the first study using OBI-3424 in humans.
*Be 18 years of age or older.<br>*Have tumor tissue collected from a previous or new biopsy to be submitted for eligibility analysis<br>*Be willing to use an effective method of contraception starting at screening until 6 months after the last dose of study drug<br>*Meet all other eligibility criteria

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org